BriaCell Therapeutics Corp. (TSX:BCT)
Canada · Delayed Price · Currency is CAD 4.930
+0.060 (1.23%)
Sep 4, 2026, 3:48 PM EST
BriaCell Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is August - July.
Millions USD. Fiscal year is Aug - Jul.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 30, 2026 | Jul '25 Jul 31, 2025 | Jul '24 Jul 31, 2024 | Jul '23 Jul 31, 2023 | Jul '22 Jul 31, 2022 | Jul '21 Jul 31, 2021 |
Net Income | -30.68 | -26.31 | -4.79 | -20.3 | -26.84 | -13.82 |
Depreciation & Amortization | 0.11 | 0.11 | 0.08 | 0.02 | 0.02 | 0.02 |
Loss (Gain) From Sale of Investments | -0.14 | - | - | - | - | - |
Loss (Gain) on Equity Investments | 0.22 | 0.22 | 0.11 | - | - | - |
Stock-Based Compensation | 1.01 | 0.78 | 1.8 | 2.19 | 3.07 | 1.97 |
Other Operating Activities | -1.16 | -1.06 | -28.38 | -2.12 | 11.66 | 6.36 |
Change in Accounts Receivable | 0.05 | 0.73 | -0.73 | 0.01 | -0.01 | 0.01 |
Change in Accounts Payable | -1.1 | -3.89 | 6.05 | 0.66 | 0.25 | -1.41 |
Change in Other Net Operating Assets | 0.86 | 1.25 | 1.74 | -4.2 | -0.63 | -0.89 |
Operating Cash Flow | -30.82 | -28.17 | -24.13 | -23.74 | -12.48 | -7.75 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 30, 2026 | Jul '25 Jul 31, 2025 | Jul '24 Jul 31, 2024 | Jul '23 Jul 31, 2023 | Jul '22 Jul 31, 2022 | Jul '21 Jul 31, 2021 |
Capital Expenditures | -0.13 | - | -0.46 | - | - | - |
Investment in Securities | -16.06 | -7.65 | -0.23 | - | - | - |
Investing Cash Flow | -16.19 | -7.65 | -0.68 | - | - | - |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 30, 2026 | Jul '25 Jul 31, 2025 | Jul '24 Jul 31, 2024 | Jul '23 Jul 31, 2023 | Jul '22 Jul 31, 2022 | Jul '21 Jul 31, 2021 |
Short-Term Debt Issued | - | - | - | - | - | 0.22 |
Total Debt Issued | - | - | - | - | - | 0.22 |
Short-Term Debt Repaid | - | - | - | - | - | -0.55 |
Total Debt Repaid | - | - | - | - | - | -0.55 |
Net Debt Issued (Repaid) | - | - | - | - | - | -0.33 |
Issuance of Common Stock | 41.43 | 45.45 | 4.42 | 4 | 6.51 | 65.33 |
Repurchase of Common Stock | - | - | - | -0.05 | -10.17 | - |
Other Financing Activities | - | - | - | - | -0.08 | - |
Financing Cash Flow | 41.43 | 45.45 | 4.42 | 3.95 | -3.74 | 65 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 30, 2026 | Jul '25 Jul 31, 2025 | Jul '24 Jul 31, 2024 | Jul '23 Jul 31, 2023 | Jul '22 Jul 31, 2022 | Jul '21 Jul 31, 2021 |
Net Cash Flow | -5.58 | 9.63 | -20.39 | -19.79 | -16.23 | 57.25 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 30, 2026 | Jul '25 Jul 31, 2025 | Jul '24 Jul 31, 2024 | Jul '23 Jul 31, 2023 | Jul '22 Jul 31, 2022 | Jul '21 Jul 31, 2021 |
Free Cash Flow | -30.95 | -28.17 | -24.58 | -23.74 | -12.48 | -7.75 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Per Share | -9.74 | -66.58 | -224.09 | -228.03 | -120.86 | -257.22 |
Levered Free Cash Flow | -20.04 | -18.89 | -10.83 | -15.87 | -6.86 | -5.83 |
Unlevered Free Cash Flow | -20.02 | -18.87 | -10.83 | -15.87 | -6.86 | -5.78 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 30, 2026 | Jul '25 Jul 31, 2025 | Jul '24 Jul 31, 2024 | Jul '23 Jul 31, 2023 | Jul '22 Jul 31, 2022 | Jul '21 Jul 31, 2021 |
Change in Working Capital | -0.2 | -1.91 | 7.05 | -3.53 | -0.39 | -2.28 |